"Diagnosing and treating TB in correctional facilities is a key component to TB elimination in the United States.
Tuberculosis (TB) is a disease caused by bacteria that are spread through the air from person to person. If not treated pro"...
- Patient Information:
Details with Side Effects
CEDAX (ceftibuten) is indicated for the treatment of individuals with mild-to-moderate infections caused by susceptible strains of the designated microorganisms in the specific conditions listed below (see DOSAGE AND ADMINISTRATION and Clinical Studies sections).
Acute Bacterial Exacerbations of Chronic Bronchitis due to Haemophilus influenzae (including β-lactamase-producing strains), Moraxella catarrhalis (including β-lactamase-producing strains), or Streptococcus pneumoniae (penicillin-susceptible strains only).
NOTE: In acute bacterial exacerbations of chronic bronchitis clinical trials where Moraxella catarrhalis was isolated from infected sputum at baseline, ceftibuten clinical efficacy was 22% less than control.
Acute Bacterial Otitis Media due to Haemophilus influenzae (including β-lactamase-producing strains), Moraxella catarrhalis (including β-lactamase-producing strains), or Streptococcus pyogenes.
NOTE: Although ceftibuten used empirically was equivalent to comparators in the treatment of clinically and/or microbiologically documented acute otitis media, the efficacy against Streptococcus pneumoniae was 23% less than control. Therefore, ceftibuten should be given empirically only when adequate antimicrobial coverage against Streptococcus pneumoniae has been previously administered.
Pharyngitis and Tonsillitis due to Streptococcus pyogenes.
NOTE: Only penicillin by the intramuscular route of administration has been shown to be effective in the prophylaxis of rheumatic fever. Ceftibuten is generally effective in the eradication of Streptococcus pyogenes from the oropharynx; however, data establishing the efficacy of the CEDAX (ceftibuten) product for the prophylaxis of subsequent rheumatic fever are not available.
DOSAGE AND ADMINISTRATION
The recommended doses of CEDAX (ceftibuten) Oral Suspension are presented in the table below. CEDAX (ceftibuten) Oral Suspension must be administered at least 2 hours before or 1 hour after a meal.
|Type of infection (as qualified in the INDICATIONS AND USAGE section of this labeling)||Daily Maximum Dose||Dose and Frequency||Duration|
|ADULTS (12 years of age and older): Acute Bacterial Exacerbations of Chronic Bronchitis due to H. influenzas (including β-actamase-producing strains), M. catarrhalis (including β-lactamase-producing strains), or Streptococcus pneumonias (penicillin-susceptible strains only). (See INDICATIONS - NOTE.) Pharyngitis and tonsillitis due to S. pyogenes. Acute Bacterial Otitis Media due to H. influenzae (including β-lactamase-producing strains), M. catarrhalis (including β-lactamase-producing strains), or S. pyogenes. (See INDICATIONS - NOTE.)||400 mg||400 mg QD||10 days|
|PEDIATRIC PATIENTS: laryngitis and tonsillitis due to S. pyogenes. Acute Bacterial Otitis Media due to H. influenzae (including β-lactamase-producing strains), and M. catarrhalis including β-lactamase-producing strains), or S. pyogenes. (See INDICATIONS - NOTE.)||400 mg||9 mg/kg QD||10 days|
|CEFTIBUTEN ORAL SUSPENSION PEDIATRIC DOSAGE CHART|
|CHILD'S WEIGHT||90 mg/5 mL||180 mg/5mL|
|10 kg 22 Ibs||1 tsp QD||1/2 tsp QD|
|20 kg 44 Ibs||2 tsp QD||1 tsp QD|
|40 kg 88 Ibs||4 tsp QD||2 tsp QD|
Pediatric patients weighing more than 45 kg should receive the maximum daily dose of 400 mg.
CEDAX (ceftibuten) Capsules and CEDAX (ceftibuten) Oral Suspension may be administered at normal doses in the presence of impaired renal function with creatinine clearance of 50 mL/min or greater. The recommendations for dosing in patients with varying degrees of renal insufficiency are presented in the following table.
|Creatinine Clearance (mL/min)||Recommended Dosing Schedules|
|> 50|| 9 mg/kg or 400 mg Q24h
(normal dosing schedule)
|30-49||4.5 mg/kg or 200 mg Q24h|
|5-29||2.25 mg/kg or 100 mg Q24h|
In patients undergoing hemodialysis two or three times weekly, a single 400-mg dose of ceftibuten capsules or a single dose of 9 mg/kg (maximum of 400 mg of ceftibuten) oral suspension may be administered at the end of each hemodialysis session.
Directions for Mixing CEDAX (ceftibuten) Oral Suspension
DIRECTIONS FOR MIXING CEDAX (ceftibuten) ORAL SUSPENSION
|Final Concentration||Bottle Size||Amount of Water||Directions|
|90 mg per 5 mL||60 mL||Suspend in 53 mL of water||First tap the bottle to loosen powder. Then add water in two portions, shaking well after each aliquot.|
|90 mL||Suspend in 78 mL of water|
|120 mL||Suspend in 103 mL of water|
|180 mg per 5 mL||30 m||Suspend in 28 mL of water|
|60 mL||Suspend in 53 mL of water|
After mixing, the suspension may be kept for 14 days and must be stored in the refrigerator. Keep tightly closed. Shake well before each use. Discard any unused portion after 14 days.
CEDAX Capsules, containing 400 mg of ceftibuten (as ceftibuten dihydrate) are white, opaque capsules imprinted with the product name and strength, are available as follows:
20 Capsules/Bottle (NDC 65224-800-22)
Store the capsules between 2° and 25°C (36° and 77°F). Replace cap securely after each opening.
CEDAX (ceftibuten) Oral Suspension is an off-white to cream-colored powder that, when reconstituted as directed, contains ceftibuten equivalent to 90 mg/5 mL or 180 mg/5 mL, supplied as follows:
90 mg/5 mL
18 mg/mL 60-mL Bottle (NDC 65224-802-02)
18 mg/mL 90-mL Bottle (NDC 65224-802-03)
18 mg/mL 120-mL Bottle (NDC 65224-802-04)
180 mg/5 mL
36 mg/mL 30-mL Bottle (NDC 65224-804-30)
36 mg/mL 60-mL Bottle (NDC 65224-804-02)
Prior to reconstitution, the powder must be stored between 2° and 25°C (36° and 77°F). Once it is reconstituted, the oral suspension is stable for 14 days when stored in the refrigerator between 2° and 8°C (36° and 46°F).
For inquires call 1-800-793-2145. Manufactured by Schering Corporation Miami Lakes, FL 33014, USA. Distributed by Pernix Therapeutics, LLC Gonzales, LA 70737, USA. Revised 04/10
Last reviewed on RxList: 5/5/2011
This monograph has been modified to include the generic and brand name in many instances.
Additional Cedax Information
Cedax - User Reviews
Cedax User Reviews
Now you can gain knowledge and insight about a drug treatment with Patient Discussions.
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Find out what women really need.